Cosmetic composition comprising a compound capable of inhibiting the FIH-1 enzyme and a compound capable of inhibiting the PHD2 enzyme for the treatment of hair loss5

Abstract

Cosmetic composition comprising a compound capable of inhibiting the FIH-1 enzyme and a compound capable of inhibiting the PHD2 enzyme for the treatment of hair loss The present invention relates to a cosmetic composition comprising: - at least one compound capable of inhibiting the FIH-1 enzyme, and - at least one compound capable of inhibiting the PHD2 enzyme. The invention also relates to a cosmetic treatment method comprising at least one step of applying this composition to keratin materials. The invention also relates to the non-therapeutic cosmetic use of this combination of active agents for inducing and / or stimulating the growth of keratin fibers and / or slowing their loss and / or for treating alopecia, in particular androgenic alopecia. Figure for abstract: none

Description

Title of the invention: Cosmetic composition comprising a compound capable of inhibiting the FIH-1 enzyme and a compound capable of inhibiting the PHD2 enzyme for the treatment of hair loss

[0001] The present invention relates to the field of scalp and keratin fiber care, more particularly to the field of keratin fiber growth and prevention of hair loss.

[0002] The present invention relates to a cosmetic composition comprising:

[0003] - at least one compound capable of inhibiting the FIH-1 enzyme, and

[0004] - at least one compound capable of inhibiting the PHD2 enzyme.

[0005] The invention also relates to a cosmetic treatment method comprising at least one step of applying this composition to keratin materials. The invention also relates to the non-therapeutic cosmetic use of this combination of active agents for inducing and / or stimulating the growth of keratin fibers and / or slowing their loss and / or for treating alopecia, in particular androgenic alopecia.

[0006] Hair growth and renewal are mainly determined by the activity of hair follicles and their matrix environment. Their activity is cyclical and essentially comprises three phases, namely the anagen phase, the catagen phase and the telogen phase.

[0007] The anagen phase (active or growth phase), which lasts several years and during which the hair grows, is followed by a very short and transient catagen phase which lasts a few weeks, then a telogen phase or resting phase which lasts a few months. At the end of the resting period, the hair falls out and another cycle begins. The hair is therefore constantly renewed and of the approximately 150,000 hairs in a head of hair, approximately 10% are at rest and will be replaced in the coming months. Natural hair loss or shedding can be estimated, on average, at a few hundred hairs per day for a normal physiological state. This process of permanent physical renewal undergoes a natural evolution during aging, the hair becomes finer and its cycles shorter. In addition, various causes can lead to significant, temporary or permanent hair loss.Hair loss, particularly alopecia, is primarily due to disruptions in hair renewal. These disruptions initially lead to an acceleration in the frequency of hair cycles, to the detriment of hair quality and then quantity. There is a progressive miniaturization of the hair follicles, with concomitant isolation. of these by progressive thickening of the perifollicular collagen matrix as well as the external connective sheath. Revascularization around the hair follicle is therefore made more difficult cycle after cycle. The hair regresses, miniaturizing until it is nothing more than non-pigmented down and this phenomenon leads to a progressive impoverishment of the hair. It is in number and average diameter that the hair follicles that make up the hair are affected. Areas are preferentially affected, notably the temporal or frontal gulfs in men, and in women, there is diffuse alopecia of the vertex.

[0008] The term alopecia also covers a whole family of hair follicle disorders that ultimately result in permanent, partial or general hair loss. This is more specifically androgenic alopecia. In a significant number of cases, early hair loss occurs in genetically predisposed individuals; this is called andro-chronogenetic alopecia; this form of alopecia particularly affects men. It is also known that certain factors such as hormonal imbalance, physiological stress, malnutrition, can accentuate the phenomenon. In addition, hair loss or alteration may be related to seasonal phenomena.

[0009] Hair loss and hair loss are often felt as distressing by those affected, especially when they are still young.

[0010] Pharmacological active agents such as minoxidil, latanoprost, fluridil, spironolactone and their combinations are known.

[0011] Other products exist and belong to the cosmetic field. Among them, we can cite for example aminexil® and stemoxydine®.

[0012] Thus, there is a need to propose combinations of active ingredients which make it possible to effectively prevent and / or treat loss of hair density.

[0013] It has also been shown in the literature that among the many factors associated with hair loss, the maintenance of stem cell potential is a key factor, and that this is impaired with age (Lecardonnel et al., Ageing and colony-forming efficiency of human hair follicle keratinocytes. Exp. Dermatol. 2013;22, 604-6). This process requires a hypoxic (oxygen-depleted) environment to activate the HIF-1 pathway, which helps maintain stem cell potential. These studies highlight that activation of the HIF-1 pathway may represent a lever to promote hair growth (Rathman-Josserand et al., Human Hair Follicle Stem / Progenitor Cells Express Hypoxia Markers. J. Investig. Dermatol. 2013;133:2094-2097).

[0014] FIH-1 protein is a transcription factor whose target genes are involved in cell proliferation and survival, angiogenesis, and the control of glycolysis. anaerobic and intracellular pH, all mechanisms directly involved in hair growth. When this pathway is not activated, the HIF-1 factor is immediately hydroxylated by the enzyme prolyl-hydroxylase PHD2, then degraded in the proteasome. On the other hand, when this pathway is activated via the decrease in oxygen content in the cell environment (hypoxia), the HIF-1 factor is then stabilized and translocated into the cell nucleus, which triggers the induction of the expression of target genes such as EGLN3, BNIP3, CA9, VEGFA (Gothié et al., MEDECINE / SCIENCES 2002; 18: 70-8).

[0015] A second enzyme with the ability to hydroxylate HIF-1 is mentioned in the literature: asparaginyl-hydroxylase FIH-1.

[0016] The applicant has surprisingly discovered that a solution comprising a compound capable of inhibiting the FIH-1 enzyme and a compound capable of inhibiting the PHD2 enzyme makes it possible to activate the HIF-1 pathway, the latter being known in the literature for its involvement in hair loss. This combination therefore has interesting properties making it possible to induce and / or stimulate the growth of keratin fibers such as hair, eyelashes, body hair, and eyebrows and / or to slow down their loss, and in particular to treat alopecia, in particular androgenic alopecia.

[0017] The subject of the invention is therefore a cosmetic composition comprising in a physiologically acceptable medium:

[0018] - at least one compound capable of inhibiting the FIH-1 enzyme, and

[0019] - at least one compound capable of inhibiting the PHD2 enzyme.

[0020] The present invention also relates to a cosmetic treatment process comprising at least one step of applying to the keratin materials a cosmetic composition according to the invention, to induce and / or stimulate the growth of keratin fibers and / or slow down their loss.

[0021] The present invention also relates to a cosmetic treatment method comprising at least one step of applying to keratin materials a cosmetic composition according to the invention, to treat alopecia, in particular androgenic alopecia.

[0022] The invention also relates to a non-therapeutic cosmetic use of a combination of active agents comprising:

[0023] - at least one compound capable of inhibiting the FIH-1 enzyme, and

[0024] - at least one compound capable of inhibiting the PHD2 enzyme

[0025] to induce and / or stimulate the growth of keratin fibers and / or slow their loss.

[0026] The invention also relates to a non-therapeutic cosmetic use of a combination of active agents comprising:

[0027] - at least one compound capable of inhibiting the FIH-1 enzyme, and

[0028] - at least one compound capable of inhibiting the PHD2 enzyme,

[0029] for treating alopecia, in particular androgenic alopecia. Definition

[0030] For the purposes of the present invention, the term “cosmetic composition” means a composition comprising a physiologically acceptable medium, i.e. a medium compatible with the skin.

[0031] For the purposes of the present invention, the term "keratin materials" means materials comprising keratin such as skin, scalp and keratin fibers. In particular, the keratin materials are preferably human keratin materials.

[0032] For the purposes of the present invention, the term “keratin fibers” means keratin fibers such as hair, eyelashes, body hair and / or eyebrows.

[0033] For the purposes of the present invention, the term “slowing down the loss of keratin fibers” means slowing down or reducing the loss of keratin fibers.

[0034] For the purposes of the present invention, the term “stimulate the growth of keratin fibers” means promoting or improving the growth of existing keratin fibers, in particular the length of existing keratin fibers.

[0035] By "inducing the growth of keratin fibers" is meant, within the meaning of the present invention, promoting or improving the growth of new keratin fibers, in particular the density of keratin fibers (by the growth of new keratin fibers).

[0036] By "treating alopecia, in particular androgenic alopecia" is meant, within the meaning of the present invention, promoting or improving the growth of new keratin fibers, or slowing down or reducing the loss of keratin fibers in people suffering from alopecia, in particular androgenic alopecia.

[0037] The term "HIF-1" (for hypoxia inducible factors, i.e. actors induced by hypoxia) is understood to mean a heterodimer consisting of the two subunits HIF-1a and HIF-1 [3 which is a transcription factor of target genes including EGLN3, BNIP3, CA9, VEGFA. - This transcription factor belongs to a biological pathway more commonly called the "HIF-1 pathway". This pathway is known in the literature for its involvement in hair loss (F Juchaux, T Sellathurai, V Perrault, F Boirre, P Delannoy, K Bakkar, J Albaud, A Gueniche, A Cheniti, S Dal Belo, L Souverain, M Le Balch, S Commo, S Thibaut, JF Michelet. “A combination of pyridine-2, 4-dicarboxylic acid diethyl ester and resveratrol stabilizes hypoxia-inducible factor 1-alpha and improves hair density in female volunteers”, Int J Cosmet Sci. 2020 Apr;42(2): 167-173). Very unstable in normoxia, the HIF-1α alpha subunit undergoes two hydroxylations in cascade, by prolyl-hydroxylases (PHD).

[0038] The term "F1H-1 enzyme" or "Factor Inhibiting HIFI" refers to a hydroxylase of the same family as PHDs and which hydroxylates a particular asparagine of HIFI, as soon as it leaves the endoplasmic reticulum. This enzyme has the protein sequence referenced Q9NWT6 in the Uniprot database, as of December 11, 2023.

[0039] The term "PHD 2 enzyme" or prolyl hydroxylase 2 domain protein is understood to mean an enzyme encoded by the EGLN1 gene. In humans, PHD2 is one of the three isoforms of hypoxia-inducible factor proline dioxygenase, also known as HIF prolyl-hydroxylase. This enzyme hydroxylates one or more specific prolines of HIF upon exiting the endoplasmic reticulum. This enzyme has the protein sequence referenced Q9GZT9 in the Uniprot database, as of December 11, 2023.

[0040] Successive hydroxylations of the HIF-1a alpha subunit by the enzymes FIH-1 and PHD2 followed by ubiquitination lead to the degradation of HIF-1 in the proteasome.

[0041] By "compound capable of inhibiting the FIH-1 enzyme" or "compound capable of inhibiting the PHD2 enzyme" is meant a compound which inhibits the expression or the enzymatic activity of the FIH-1 and PHD2 enzymes respectively, for example in keratinocytes, such as human keratinocytes. This inhibition can be evaluated by monitoring the activity of the HIF-1 factor which results in the induction of the expression of genes under the control of this factor such as EGLN3, BNIP3, CA9, VEGFA.

[0042] By "salt" is meant an addition salt with an organic or mineral acid or base. The addition salts with an acid are in particular chosen from addition salts with acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, citric acid, succinic acid, tartaric acid, lactic acid, tosylic acid, benzenesulfonic acid, phosphoric acid or acetic acid. The addition salts with a base are in particular chosen from addition salts with bases such as alkali metal hydroxides, alkaline earth metal hydroxides, ammonia, amines or alkanolamines.

[0043] Compound capable of inhibiting the enzyme FIH-1

[0044] Thus, in a preferred embodiment of the invention, said at least one compound capable of inhibiting the FIH-1 enzyme is chosen from niacinamide (CAS number: 98-92-0), ethylenediamine disuccinic acid and its salts such as trisodium ethylenediamine disuccinate (CAS number: 178949-82-1), arginine (CAS number: 7200-25-1) and its salts, mannose-6-phosphoric acid and its salts such as sodium mannose phosphate (CAS number: 40436-60-0), N-acetylcysteine ​​(CAS number: 616-91-1) and its salts, niacin (CAS number: 59-67-6) and its salts, ethylhexyl gallate (CAS number: 34531-26-5), L-ascorbyl-2-phosphoric acid and its salts such as Magnesium L-ascorbyl-2-phosphate (CAS No. 113170-55-1), labaicalein (CAS No. 491-67-8), usnic acid (CAS No. 125-46-2) and its salts, methyl nicotinate (CAS No. 93-60-7), adenosine triphosphate (CAS No. 56-65-5) and its salts, methyl L-tyrosinate and its salts such as hydrochloride (CAS No. 3417-91-2), isoleucine (CAS No. 443-79-8) and its salts, aloesin (CAS No. 30861-27-9), pyridoxine dioctenoate ester (CAS No. 59599-61-0);

[0045] their solvates such as hydrates, extracts comprising them, and mixtures thereof.

[0046] According to a more preferred embodiment, said at least one compound capable of inhibiting the FIH-1 enzyme is chosen from niacinamide (CAS number: 98-92-0), baicalein (CAS number: 491-67-8), methyl nicotinate (CAS number: 93-60-7), their solvates such as hydrates, extracts comprising them, and mixtures thereof.

[0047] According to an even more preferred embodiment, said at least one compound capable of inhibiting the FIH-1 enzyme comprises niacinamide, more preferably said at least one compound capable of inhibiting the FIH-1 enzyme is niacinamide. According to an even more preferred embodiment, the only compound capable of inhibiting the FIH-1 enzyme of the composition is niacinamide.

[0048] Preferably, the composition comprises from 0.00001% to 5% by weight of compound(s) capable of inhibiting the FIH-1 enzyme in total relative to the total weight of the composition, preferably from 0.0001% to 4% by weight, preferentially from 0.001% to 3%, relative to the total weight of the composition.

[0049] Compound capable of inhibiting the PHD2 enzyme

[0050] In a preferred embodiment of the invention, said at least one compound capable of inhibiting the PHD2 enzyme is chosen from [6]-gingerol (CAS number: 23513-14-6), [8]-gingerol (CAS number: 23513-08-8),

[10] -gingerol (CAS number: 23513-15-7), hinokitiol (CAS number: 499-44-5), isoniacinamide (CAS number: 1453-82-3), nordihydroguaiaretic acid (CAS number: 500-38-9) and its salts, isoquercetin (CAS number: 21637-25-2), apigenin-7-O-(6"-O-4-coumaroyl)-beta-glucopyranoside (Echinacin, CAS number: 105815-90-5), rutin (CAS number: 153-18-4), hesperidin (CAS number: 520-26-3), arbutin (CAS number: 497-76-7), acetyl methionine (CAS number: 1115-47-5) and its salts, chlorogenic acid (CAS number: 327-97-9) and its salts, oxothiazolidinecarboxylic acid (CAS number: 19771-63-2) and its salts, hydroxyphenylpropamidobenzoic acid (CAS number: 697235-49-7) and its salts, azelamide MEA (CAS number: 242132-61-2) and its salts,curcumin (CAS number: 458-37-7), aleuritic acid (CAS number: 17941-34-3) and its salts, hydroxycaprylic acid (CAS number: 617-73-2) and its salts, dipropylene glycol salicylate (CAS number: 55940-73-3) and its salts, hydroxymethoxybenzyl, pelargonamide (CAS number: 2444-46-4), naringin (CAS number: 10236-47-2), benzyl salicylate (CAS number: 118-58-1), capryloyl salicylic acid (CAS number: 70424-62-3) and its salts, cyclic adenosine monophosphate (CAS number: 60-92-4) and its salts, ethyl hydroxypyrone (CAS number: 4940-11-8), ferulic acid (CAS number: 1135-24-6) and its salts, ethyl ferulate (CAS number: 4046-02-0), silibinin (CAS number: 22888-70-6), cyclic guanosine monophosphate and its salts such as sodium salt (CAS number: 40732-48-7), panthenyl ethyl ether (CAS number: 667-83-4), methyl salicylate (CAS number: 119-36-8), 2-o-ethyl ascorbic acid (CAS number: 112894-37-8), diosmin (CAS number: 520-27-4), esculin (CAS number: 531-75-9) and pyroglutamic acid (CAS number: 149-87-1);

[0051] their solvates such as hydrates, extracts comprising them, and mixtures thereof.

[0052] In a more preferred embodiment of the invention, said at least one compound capable of inhibiting the PHD2 enzyme is chosen from [6]-gingerol (CAS number: 23513-14-6), [8]-gingerol,

[10] -gingerol, hinokitiol (CAS number: 499-44-5), isoniacinamide (CAS number: 1453-82-3), ethyl hydroxypyrone (CAS number: 4940-11-8), ethyl ferulate (CAS number: 4046-02-0), methyl salicylate (CAS number: 119-36-8);

[0053] their solvates such as hydrates, extracts comprising them, and mixtures thereof.

[0054] In an even more preferred embodiment of the invention, said at least one compound capable of inhibiting the PHD2 enzyme is selected from [6]-gingerol (CAS number: 23513-14-6), [8]-gingerol,

[10] -gingerol, their solvates such as hydrates, extracts comprising them, and mixtures thereof.

[0055] Preferably, said at least one compound capable of inhibiting the PHD2 enzyme is chosen from [6]-gingerol (CAS number: 23513-14-6), its solvates such as hydrates, extracts comprising it, and mixtures thereof. According to an even more preferred embodiment, the only compound capable of inhibiting the PHD2 enzyme of the composition is chosen from [6]-gingerol (CAS number: 23513-14-6), its solvates such as hydrates, extracts comprising it.

[0056] More preferably, said at least one compound capable of inhibiting the PHD2 enzyme comprises a gingerol, more preferably [6]-gingerol (CAS number: 23513-14-6). Even more preferably, said at least one compound capable of inhibiting the PHD2 enzyme is [6]-gingerol (CAS number: 23513-14-6). According to an even more preferred embodiment, the only compound capable of inhibiting the PHD2 enzyme of the composition is [6]-gingerol.

[0057] Preferably, said at least one compound capable of inhibiting the PHD2 enzyme is present in the composition according to the invention in a content ranging from 0.00001% to 5% by weight of compound(s) capable of inhibiting the PHD2 enzyme total relative to the total weight of the composition, preferably from 0.0001% to 4%, even better 0.001% to 3% by weight of compound(s) capable of inhibiting the PHD2 enzyme total relative to the total weight of the composition.

[0058] The [6]-gingerol, [8]-gingerol and / or

[10] -gingerol may be in the form of extracts, by any extraction process known per se, from plants belonging to the Zingiberaceae family and, more particularly, from those belonging to the genus Zingiber and in particular to the species Zingiber officinalis (commonly called ginger). More particularly, the [6]-gingerol, [8]-gingerol and / or

[10] -gingerol may be in the form of rhizome extracts of these plants (also referred to herein as ginger root extract).

[0059] In particular, the ginger rhizome extract may be in the form of ground material, powder or liquid, it is preferably in the form of liquid.

[0060] The ginger rhizome extract may in particular be obtained by supercritical CO2 extraction from ginger rhizome fragments, for example ginger rhizome powder. The ginger rhizome extract used is preferably an extract obtained by supercritical CO2 extraction such as that marketed under the name GINGER CO2 by the company FLAVEX.

[0061] [6]-gingerol, [8]-gingerol and / or

[10] -gingerol may also be obtained by chemical synthesis, for example according to the processes described by BANNO and MUKAIYAMA, Bull. Chem. Soc. Japan, 49(5), 1453-1454 (1976). Said gingerols may also be obtained by purification or enrichment of natural plant extracts such as extracts of plants belonging to the Zingiberaceae family, in particular those belonging to the genus Zingiber, more particularly to the species Zingiber officinalis.

[0062] Thus, according to one embodiment of the invention, said at least one compound capable of inhibiting the PHD2 enzyme comprises an extract of ginger rhizome, more preferably said at least one compound capable of inhibiting the PHD2 enzyme is an extract of ginger rhizome.

[0063] In the case where said at least one compound capable of inhibiting the PHD2 enzyme is in the form of ginger rhizome extract, said extract is then preferably present in a content ranging from 0.00003 to 1% by weight, preferably from 0.0001 to 0.5% by weight, more preferably 0.001 to 0.3% by weight, relative to the total weight of the composition.

[0064] In one embodiment, the composition according to the invention does not comprise any active agents other than at least one compound capable of inhibiting the FIH-1 enzyme, and at least one compound capable of inhibiting the PHD2 enzyme.

[0065] The composition preferably contains a physiologically acceptable medium.

[0066] This physiologically acceptable medium may more particularly consist of water and optionally of a physiologically acceptable organic solvent chosen for example from lower alcohols comprising from 1 to 8 carbon atoms and in particular 1 to 6 carbon atoms, such as ethanol, isopropanol, propanol, butanol; polyethylene glycols having from 6 to 80 ethylene oxides; polyols such as propylene glycol, isoprene glycol, butylene glycol, glycerin, sorbitol, 1,3-propanediol.

[0067] It may also be an anhydrous medium, in particular an oily medium containing oils and / or fatty substances other than oils.

[0068] When the physiologically acceptable medium is an aqueous medium, it has a pH compatible with the skin, preferably ranging from 3 to 8 and better still from 4 to 7.

[0069] When the composition comprises an aqueous or hydroalcoholic medium, it is possible to add a fatty (or oily) phase to this medium.

[0070] The composition according to the invention is in particular a composition intended for topical application to the scalp and / or keratin fibers.

[0071] The composition according to the invention may also comprise one or more additional compounds chosen in particular from surfactants, preferably chosen from non-ionic, anionic, cationic and amphoteric surfactants, conditioning agents preferably chosen from cationic polymers, silicones, polymeric or non-polymeric, natural or synthetic thickening agents, UV filters, fillers such as nacres, titanium dioxide, resins and clays, perfumes, peptizers, vitamins, preservatives, acidic agents, alkaline agents, reducing agents, oxidizing agents, additional active agents other than the extract according to the invention intended to further improve the activity on regrowth and / or on slowing down hair loss, and having already been described for this activity, such as nicotinic acid esters, including in particular tocopherol nicotinate,benzyl nicotinate and C1-C6 alkyl nicotinates such as methyl or hexyl nicotinates; hair regrowth promoting agents chosen from pyrimidine 3-oxide derivatives such as 2,4-diaminopyrimidine-3-N-oxide (Aminexil), pyridine-dicarboxylate derivatives or one of its salts such as those described in FR2838336 such as pyridine-2,4-dicarboxylate dimethyl ester; and a mixture of these compounds.

[0072] The above additional compounds may each be present in an amount varying from 0.01% to 20% by weight relative to the total weight of the composition.

[0073] The composition according to the invention is intended for cosmetic use by topical application to the scalp and / or keratin fibers, and more specifically to the scalp, hair and eyelashes, body hair, eyebrows.

[0074] Depending on the method of application, this composition can be presented in all the galenic forms normally used in the cosmetic field, such as lotion, serum, milk, cream, gel, ointment, pomade, powder, balm, patch, soaked pad, soap, bar, foam. It can be formulated in the form of an emulsion, such as a direct oil-in-water emulsion or a reverse water-in-oil emulsion.

[0075] For topical application to the scalp and / or keratin fibers, the composition may have the form in particular of an aqueous or hydro-alcoholic solution or suspension, of an emulsion or dispersion of liquid or semi-liquid consistency obtained by dispersing a fatty phase in an aqueous phase (O / W) or vice versa (W / O), of a dispersion or emulsion of soft consistency, of an aqueous or hydro-alcoholic gel, or of microcapsules or microparticles, or of vesicular dispersions of ionic and / or non-ionic type.

[0076] The composition may also be in the form of a foam or in the form of an aerosol composition also comprising a pressurized propellant.

[0077] Preferably, for topical application to the scalp and / or keratin fibers, in particular the scalp or hair, the composition may be in the form of a hair lotion, a shampoo, a conditioner, a hair styling product (hairspray, styling product, styling gel), a hair mask, a cream or a foaming hair cleansing gel.

[0078] According to a preferred embodiment, the composition is in the form of a cream or lotion, shampoo or conditioner.

[0079] Method

[0080] The present invention also relates to a non-therapeutic cosmetic treatment process comprising the application to keratin materials of the composition described above, to induce and / or stimulate the growth of keratin fibers and / or slow their loss.

[0081] The present invention also relates to a non-therapeutic cosmetic treatment method comprising the application to keratin materials of the composition described above, for treating alopecia, in particular androgenic alopecia.

[0082] In particular, the method comprises applying the composition to the scalp and / or fibers, then, optionally, rinsing, after a leave-on time of the composition which may vary from 1 minute to 30 minutes.

[0083] Preferably, the cosmetic composition is not rinsed.

[0084] Use

[0085] The subject of the present invention is the non-therapeutic cosmetic use of a combination of active agents comprising:

[0086] - at least one compound capable of inhibiting the FIH-1 enzyme, and

[0087] - at least one compound capable of inhibiting the PHD2 enzyme,

[0088] to induce and / or stimulate the growth of keratin fibers and / or slow their loss.

[0089] The present invention also relates to the non-therapeutic cosmetic use of a combination of active agents comprising:

[0090] - at least one compound capable of inhibiting the FIH-1 enzyme, and

[0091] - at least one compound capable of inhibiting the PHD2 enzyme,

[0092] for treating alopecia, in particular androgenic alopecia.

[0093] Preferably, the combination of active agents used according to the invention comprises the same active agents in the same concentrations and / or proportions as described above for the composition according to the invention.

[0094] Furthermore, the expression “at least one” used in the present description is equivalent to the expression “one or more”.

[0095] The invention will appear more clearly on reading the example which follows, given solely as a non-limiting example. Example:

[0096] 1. Example 1- Cosmetic composition: anti-hair loss lotion#

[0097] The following composition was prepared.

[0098] [Tables 1] Compound Concentration (g / 100g) Acrylates / methacrylate copolymer beheneth-25. 2 Gingerols 0.02 Niacinamide 3 PEG-40 hydrogenated castor oil 0.1 Ethanol 40 Fragrance 0.4 Water Qsp 100

[0099] The composition was applied to the scalp and hair and helps to slow down hair loss.

Claims

Claims

1. Cosmetic composition comprising in a physiologically acceptable medium: - at least one compound capable of inhibiting the FIH-1 enzyme, said at least one compound capable of inhibiting the FIH-1 enzyme being chosen from niacinamide, ethylenediamine disuccinic acid and its salts, arginine and its salts, mannose-6-phosphoric acid and its salts, N-acetylcysteine ​​and its salts, niacin and its salts, ethylhexyl gallate, L-ascorbyl-2-phosphoric acid and its salts, baicalein, usnic acid and its salts, methyl nicotinate, adenosine triphosphate and its salts, methyl L-tyrosinate and its salts, isoleucine and its salts, aloesin, pyridoxine dioctenoate ester; their solvates, the extracts comprising them, and their mixtures; and - at least one compound capable of inhibiting the PHD2 enzyme, said at least one compound capable of inhibiting the PHD2 enzyme being chosen from [6]-gingerol, [8]-gingerol, [10]-gingerol, hinokitiol, isoniacinamide,nordihydroguaiaretic acid and its salts, isoquercetin, apigenin-7-O-(6"-O-4-coumaroyl)-beta-glucopyranoside, rutin, hesperidin, arbutin, acetyl methionine and its salts, chlorogenic acid and its salts, oxothiazolidinecarboxylic acid and its salts, hydroxyphenylpropamidobenzoic acid and its salts, azelamide MEA and its salts, curcumin, aleuritic acid and its salts, hydroxycaprylic acid and its salts, dipropylene glycol salicylate and its salts, hydroxymethoxybenzyl pelargonamide, naringin, benzyl salicylate, capryloyl salicylic acid and its salts, cyclic adenosine monophosphate and its salts, ethyl hydroxypyrone, ferulic acid and its salts, ethyl ferulate, silibinin, cyclic guanosine monophosphate and its salts, panthenyl ethyl ether, methyl salicylate, 2-o-ethyl ascorbic acid, diosmin, esculin and pyroglutamic acid; their solvates such as hydrates, extracts comprising them,and their mixtures.,

2. A composition according to claim 1, wherein said at least one compound capable of inhibiting the FIH-1 enzyme comprises niacinamide.

3. A composition according to any one of claims 1 to 2, wherein said at least one compound capable of inhibiting the PHD2 enzyme comprises a ginger rhizome extract.

4. Composition according to any one of claims 1 to 3, in which said at least one compound capable of inhibiting the PHD2 enzyme comprises a gingerol, and more preferably [6]-gingerol.

5. Non-therapeutic cosmetic treatment process comprising at least one step of applying to keratin materials a cosmetic composition according to any one of claims 1 to 4, to induce and / or stimulate the growth of keratin fibers and / or slow their loss in a subject presenting a normal physiological state.

6. Method according to claim 5, in which the keratin fibers are chosen from hair, eyelashes, body hair, and / or eyebrows.

7. Non-therapeutic cosmetic use of a combination of active agents comprising: - at least one compound capable of inhibiting the FIH-1 enzyme, said at least one compound capable of inhibiting the FIH-1 enzyme being chosen from niacinamide, ethylenediamine disuccinic acid and its salts, arginine and its salts, mannose-6-phosphoric acid and its salts, N-acetylcysteine ​​and its salts, niacin and its salts, ethylhexyl gallate, L-ascorbyl-2-phosphoric acid and its salts, baicalein, usnic acid and its salts, methyl nicotinate, adenosine triphosphate and its salts, methyl L-tyrosinate and its salts, isoleucine and its salts, aloesin, pyridoxine dioctenoate ester; their solvates, the extracts comprising them, and their mixtures;and - at least one compound capable of inhibiting the PHD2 enzyme, said at least one compound capable of inhibiting the PHD2 enzyme being chosen from [6]-gingerol, [8]-gingerol, [10]-gingerol, hinokitiol, isoniacinamide, nordihydroguaiaretic acid and its salts, isoquercetin, apigenin-7-O-(6"-O-4-coumaroyl)-beta-glucopyranoside, rutin, hesperidin, arbutin, acetyl methionine and its salts, chlorogenic acid and its salts, oxothiazolidinecarboxylic acid and its salts, hydroxyphenylpropamidobenzoic acid and its salts, azelamide MEA and its salts, curcumin, aleuritic acid and its salts, hydroxycaprylic acid and its salts, dipropylene glycol salicylate and; its salts, hydroxymethoxybenzyl pelargonamide, naringin, benzyl salicylate, capryloyl salicylic acid and its salts, cyclic adenosine monophosphate and its salts, ethyl hydroxypyrone, ferulic acid and its salts, ethyl ferulate, silibinin, cyclic guanosine monophosphate and its salts, panthenyl ethyl ether, methyl salicylate, 2-o-ethyl ascorbic acid, diosmin, esculin and pyroglutamic acid; their solvates such as hydrates, extracts comprising them, and mixtures thereof; for inducing and / or stimulating the growth of keratin fibers and / or slowing their loss in a subject in a normal physiological state.

8. Combination of active agents for use in the treatment of alopecia, in particular androgenic alopecia, said combination of active agents comprising: - at least one compound capable of inhibiting the FIH-1 enzyme, said at least one compound capable of inhibiting the FIH-1 enzyme being chosen from niacinamide, ethylenediamine disuccinic acid and its salts, arginine and its salts, mannose-6-phosphoric acid and its salts, N-acetylcysteine ​​and its salts, niacin and its salts, ethylhexyl gallate, L-ascorbyl-2-phosphoric acid and its salts, baicalein, usnic acid and its salts, methyl nicotinate, adenosine triphosphate and its salts, methyl L-tyrosinate and its salts, isoleucine and its salts. salts, aloesin, pyridoxine dioctenoate ester; their solvates, extracts comprising them, and mixtures thereof;and - at least one compound capable of inhibiting the PHD2 enzyme, said at least one compound capable of inhibiting the PHD2 enzyme being chosen from [6]-gingerol, [8]-gingerol, [10]-gingerol, hinokitiol, isoniacinamide, nordihydroguaiaretic acid and its salts, isoquercetin, apigenin-7-O-(6"-O-4-coumaroyl)-beta-glucopyranoside, rutin, hesperidin, arbutin, acetyl methionine and its salts, chlorogenic acid and its salts, oxothiazolidinecarboxylic acid and its salts, hydroxyphenylpropamidobenzoic acid and its salts, azelamide MEA and its salts, curcumin, aleuritic acid and its salts, hydroxycaprylic acid and its salts, dipropylene glycol salicylate and its salts, hydroxymethoxybenzyl pelargonamide, naringin; benzyl salicylate, capryloyl salicylic acid and its salts, cyclic adenosine monophosphate and its salts, ethyl hydroxypyrone, ferulic acid and its salts, ethyl ferulate, silibinin, cyclic guanosine monophosphate and its salts, panthenyl ethyl ether, methyl salicylate, 2-o-ethyl ascorbic acid, diosmin, esculin and pyroglutamic acid; their solvates such as hydrates, extracts comprising them, and mixtures thereof.